Is Zepbound or Wegovy More Effective?
A recent meta-analysis found that GLP-1 medications containing tirzepatide, such as Zepbound and Mounjaro, result in greater weight loss than semaglutide or liraglutide. According to the study, tirzepatide users lost 15-20% of their body weight, compared to 12-13% for semaglutide and approximately 5% for liraglutide.
Pooja Gokhale, a doctoral student in the University of Georgia College of Pharmacy and the review’s corresponding author, stated in a press release that tirzepatide “seems to be the better option” for those seeking maximum weight loss without increased rates of gastrointestinal problems or nausea.
The findings arrive as GLP-1 drugs grow in popularity, with approximately 2 in 5 U.S. adults meeting the criteria for obesity.
Why is tirzepatide more effective for weight loss?
The increased effectiveness of tirzepatide is attributed to its dual mechanism. While semaglutide and liraglutide target only GLP-1 receptors, tirzepatide targets both GLP-1 receptors and another gut hormone called GIP.
These medications work by mimicking natural gut hormones to slow digestion, lower blood sugar, and increase feelings of fullness. Researchers suggest the way the body processes these drugs also impacts results.
Liraglutide (Saxenda) has a half-life of about 13 hours, necessitating daily injections. In contrast, tirzepatide and semaglutide have longer half-lives of five days and one week, respectively, which allows for weekly dosing.
How do semaglutide and liraglutide compare?
Semaglutide (Ozempic, Wegovy) outperformed liraglutide in weight loss, with participants losing 12-13% of their body weight compared to the 5% seen with liraglutide users.
Clare Thompson, a general practitioner and weight management services lead at Cadogan Clinic in the United Kingdom, noted that semaglutide offers specific advantages. It has been on the market longer and possesses more robust long-term data regarding the reduction of strokes, heart attacks, and renal disease.
Semaglutide is also often less expensive than tirzepatide. Additionally, it is available as an oral pill, providing an alternative for patients who avoid injections.
What options are available for oral medication?
The Food and Drug Administration (FDA) first approved oral semaglutide (Rybelsus) to treat type 2 diabetes, though it may also assist with weight loss. In December 2025, the FDA approved an oral version of Wegovy specifically for weight loss.
Thompson emphasizes that pharmacological treatment should not be a standalone solution. She states that the best outcomes occur when these drugs are combined with sustainable lifestyle changes, including regular physical activity, improved nutrition, and resistance training to preserve muscle mass.
What happens next for GLP-1 therapy?
Future research may determine if the higher weight loss percentages associated with tirzepatide lead to superior long-term health benefits compared to other GLP-1 therapies, according to Thompson.
Medical providers are likely to continue using personalized approaches, as Thompson describes obesity as a chronic condition where “there isn’t a one-size-fits-all” treatment.
Frequently Asked Questions
Which GLP-1 medication resulted in the highest weight loss?
Tirzepatide (Zepbound, Mounjaro) showed the highest weight loss, with users losing between 15-20% of their body weight.
What is the difference between tirzepatide and semaglutide’s mechanism?
Semaglutide targets GLP-1 receptors, while tirzepatide has a dual mechanism that targets both GLP-1 receptors and the gut hormone GIP.
Are there non-injectable versions of these drugs?
Yes, semaglutide is available as an oral pill (Rybelsus), and the FDA approved an oral form of Wegovy for weight loss in December 2025.
Which factor—weight loss percentage or long-term heart health data—do you believe is more important when choosing a medication?